Quercetin as a dual metabolic reprogramming agent in bladder cancer: exogenous blockade via microbiota and endogenous blockade via PSPH
In preclinical models, quercetin reduced L-serine availability in bladder cancer cells through two simultaneous mechanisms — gut microbiota remodeling and PSPH downregulation — but no human data exist and clinical relevance is undetermined.
| Population | Preclinical bladder cancer models (cell lines and murine models implied in the text) |
|---|---|
| Intervention | Oral quercetin, with or without viable Escherichia coli Nissle 1917 (EcN) administration |
| Comparator | Untreated controls or vehicle (details not specified in the available summary) |
| Outcome | Intratumoral L-serine availability; Intratumoral PSPH expression; Nucleotide pool (ATP/GTP); Apoptosis and cell cycle arrest; Gut microbiota alpha diversity; Enrichment of EcN and beneficial microbial taxa; Systemic tolerability and hepatorenal toxicity |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Intratumoral L-serine availability | not quantified; positive correlation with tumor burden reported (no CI) | — | Very low | — | 1 studies |
| Intratumoral PSPH expression | downregulation reported; in the quantitative effect size or CI provided | — | Very low | — | 1 studies |
| Nucleotide pool (ATP/GTP) | reduction reported; in the quantitative effect size or CI provided | — | Very low | — | 1 studies |
| Apoptosis and cell cycle arrest | induction reported; in the quantitative effect size or CI provided | — | Very low | — | 1 studies |
| Gut microbiota alpha diversity | significant reduction reported; in the quantitative effect size or CI provided | — | Very low | — | 1 studies |
| Enrichment of EcN and beneficial microbial taxa | enrichment of Blautia, Parabacteroides, EcN reported; in the quantitative effect size or CI provided | — | Very low | — | 1 studies |
| Systemic tolerability and hepatorenal toxicity | favorable tolerability claimed; in the quantitative safety data or CI provided | — | Very low | — | 1 studies |
Context
Bladder cancer cells depend on L-serine for purine synthesis, one-carbon metabolism, and redox homeostasis. Dietary restriction alone fails because tumors activate the de novo serine synthesis pathway (SSP) as compensation. A dual-blockade strategy — exogenous and endogenous — is proposed to circumvent this metabolic plasticity.
What the study showed
Quercetin accumulating in the colon reversed dysbiosis, reduced alpha diversity, and enriched taxa including Blautia, Parabacteroides, and EcN, which accelerated intestinal L-serine degradation. L-serine was the most pivotal differential metabolite in untargeted metabolomic profiling, with concentration positively correlated with tumor burden. Internally, quercetin downregulated PSPH (confirmed by RNA-seq and functional validations), blocking de novo serine synthesis, reducing the global nucleotide pool, and inducing cell cycle arrest and apoptosis. No absolute numerical data, 95% CI, or quantified effect sizes are reported in the available text.
How it was done
Preclinical study published in Acta Pharmaceutica Sinica B (2026). The available full text is an editorial commentary on the primary article by Zhai et al., not the original primary article. Methods include RNA-seq, untargeted metabolomics, microbiota manipulation, and bladder cancer models; exact sample sizes, duration, and species are not provided in this document.
Effect magnitude
No quantitative effect sizes (RR, OR, SMD, MD) with 95% CI are reported in the available text. Effect magnitudes are described qualitatively only ('significantly reduced', 'robust positive correlation').
Risk of bias
The analyzed document is a commentary/editorial on the primary article by Zhai et al., not the full primary study — a critical limitation for bias risk assessment (RoB 2 or ROBINS-I not applicable without access to primary data). All work is preclinical; no human evidence is presented. Oral quercetin pharmacokinetics in humans is known to be limited (low systemic bioavailability), which is not discussed. Immunosuppressed models do not capture adaptive immune system interactions.
What this study does NOT prove
This study does NOT prove efficacy or safety of quercetin in humans with bladder cancer. It does NOT prove causality between L-serine depletion and clinical tumor regression, nor that the microbiota remodeling observed in animal models is reproducible in patients.
In clinical practice
There is no basis to recommend quercetin to bladder cancer patients outside a clinical trial setting. Clinicians should treat these findings as a preclinical mechanistic hypothesis with no current therapeutic application. Dietary manipulation of serine without supervision may have unpredictable metabolic consequences.
Limitations
The analyzed document is a commentary/editorial on the primary article by Zhai et al., not the full primary study — a critical limitation for bias risk assessment (RoB 2 or ROBINS-I not applicable without access to primary data). All work is preclinical; no human evidence is presented. Oral quercetin pharmacokinetics in humans is known to be limited (low systemic bioavailability), which is not discussed. Immunosuppressed models do not capture adaptive immune system interactions.
What is still missing
Trials in immunocompetent models to evaluate synergy with immune checkpoint inhibitors and confirm that dual serine blockade does not activate alternative compensatory pathways. Pharmacokinetic studies in humans to verify whether oral quercetin reaches effective colonic concentrations.
Technical appendix
Version history
- 1.0 · 2026-10-28 — Auto-generated under Evidence Standard v1.0